Mitochondrial reprogramming in chronic diseases: Emerging molecular mechanisms and therapeutic opportunities

Mitochondria are dynamic signalling and metabolic organelles whose functions extend beyond adenosine triphosphate production to redox regulation, calcium handling, innate immunity, cell-death control and epigenetic regulation. In chronic diseases, persistent nutrient excess, hypoxia, inflammation, environmental stress and ageing can remodel mitochondrial metabolism and quality control systems. This review synthesizes molecular mechanisms through which mitochondrial reprogramming contributes to cardiometabolic disorders, neurodegeneration, chronic inflammatory conditions, cancer and fibrotic disease. Key processes include altered oxidative phosphorylation, electron transport chain remodelling, reactive oxygen species signalling, mitochondrial DNA release, fission fusion imbalance, impaired mitophagy, changes in mitochondrial biogenesis, and altered tricarboxylic acid cycle metabolites. These processes interact with AMP activated protein kinase, mechanistic target of rapamycin, hypoxia inducible factor 1, sirtuins, NRF2, cGAS STING and NLRP3 inflammasome pathways. The resulting phenotype is context dependent: mitochondrial adaptations may initially preserve survival, yet persistent or poorly resolved responses can promote inflammation, insulin resistance, neuronal vulnerability, tumour progression or extracellular matrix deposition. Emerging interventions include exercise and dietary approaches, metabolic modulators, targeted antioxidants, mitophagy and biogenesis regulators, NAD+ precursors, mitochondrial transfer, and gene or RNA based strategies. Their promise is tempered by tissue specificity, uncertain target engagement, dose dependent effects, biomarker limitations and the gap between preclinical models and clinical outcomes. We argue that successful translation will require disease stage aware stratification, direct functional measurements, longitudinal biomarkers and combination strategies that restore mitochondrial homeostasis without suppressing physiological signalling. Mitochondrial reprogramming is therefore best viewed as a modifiable network rather than a single lesion, offering multiple therapeutic entry points while demanding careful validation in human disease. Careful validation is essential before clinical implementation.